Troxatyl™ (Cytotoxic Chemotherapeutic)

DRUG2 trials

Sponsors

SGX Pharmaceuticals, Inc.

Conditions

Acute Myelogenous LeukemiaNeoplasms

Phase 1

Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors

TerminatedNCT00104286

SGX Pharmaceuticals, Inc.Neoplasms

Start: 2003-01-31End: 2005-11-30Target: 50Updated: 2006-11-03

Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

TerminatedNCT00104468

SGX Pharmaceuticals, Inc.Acute Myelogenous Leukemia

Start: 2003-04-30End: 2007-06-30Target: 50Updated: 2008-01-17